Dr. Kavita Patel informed CNBC on Tuesday she thinks the Food and Drug Administrations recommendation that states pause using Johnson & & Johnsons single-shot Covid vaccine is likely to have lasting effects on the countrys efforts to combat the pandemic.”This is a terrible blow to this J&J vaccine effort in the United States,” stated Patel, a primary care physician in Washington who worked on health-care initiatives in the Obama administration while working as director of policy for the Office of Intergovernmental Affairs and Public Engagement.In an interview on “Squawk Box,” Patel said the supply of the two-shot vaccines from Pfizer and Moderna wont have the ability to quickly comprise the need produced by the J&J pause. This will postpone U.S. vaccination efforts, she added.The FDAs recommendation, released earlier Tuesday, came after six J&J vaccine recipients in the U.S. established serious and unusual blood-clotting issues.In a tweet, the U.S. regulator stated its action was being taken “out of an abundance of care.”All 6 cases happened in ladies ages 18 to 48, with symptoms developing 6 to 13 days after they received the shot.As of now, J&J said theres “no clear causal relationship” in between these uncommon occasions and the vaccine. The U.S. drug giant also said its working with regulators.Patel said the stop– even if it shows momentary– might make complex efforts to fight vaccine hesitancy in the U.S. “To anybody who is reluctant, I would inform you: Think about the reality we are still dealing with deaths, hospitalizations and the effects of even moderate cases of Covid,” Patel said. “Vaccines have actually been revealed to be efficient in all those circumstances. Preventing death is a much better choice.”While she anticipates Moderna and Pfizer will be able to “pick up some of that slack” ultimately, Patel worried “it will take time” for those other vaccine makers to have extra dosages offered in the U.S.One specific difficulty with stopping the administration of J&Js vaccine is that it needs simply a single shot, Patel said, whereas Moderna and Pfizers mRNA vaccines require two dosages for complete immunity protection.”In the next one to three weeks, we simply cant substitute it,” said Patel, an NBC News medical factor and nonresident fellow at the Brookings Institution. “This will delay our vaccination efforts.” To compensate, the U.S. might desire to consider pushing back the administration of second doses for receivers of Moderna and Pfizers vaccines, Patel suggested.White House primary medical consultant Dr. Anthony Fauci has opposed calls to do so at earlier points in the pandemic.Modernas second dosage is expected to be offered four weeks after the very first, while the suggestion for the Pfizer-BioNTech vaccine is three weeks apart.”Youre going to hear a renewal for calls to postpone that second shot so we can get as lots of very first shots into the arms. Its not an unreasonable thing to do, to consider now,” stated Patel.”If we press out the second dosages of Moderna or Pfizer a couple of weeks, this might really still assist us select up some of that slack in a quicker rate,” she included.